Activating somatic mutations of FGFR2 have been reported in some cancers including lung squamous cell carcinoma, gastric cancer, cervical carcinoma, and endometrial carcinoma, implicating its role in cancer development [60]–[62]. Here, FGFR2 is linked to endometrial carcinoma.